Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.
Back
ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung Cancer
Sponsored in part by Regeneron. Content independently created by OncLive. A panel of experts discuss updates in immunotherapy for advanced non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment decision-making.
ELCC Updates in Immunotherapy and Beyond for Non–Small Cell Lung Cancer
Episodes
All
All
The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.
Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.
Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.
Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.
Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.
Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.
The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.
Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.
Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
5